Bioprotective carnitinoids: lipoic acid, butyrate, and mitochondria-targeting to treat radiation injury: mitochondrial drugs come of age
Date
2015-06-01
Authors
Steliou, Kosta
Faller, Douglas V.
Pinkert, Carl A.
Irwin, Michael H.
Moos, Walter H.
Version
Accepted manuscript
OA Version
Citation
Kosta Steliou, Douglas V Faller, Carl A Pinkert, Michael H Irwin, Walter H Moos. 2015. "Bioprotective carnitinoids: lipoic acid, butyrate, and mitochondria-targeting to treat radiation injury: mitochondrial drugs come of age." Drug Development Research, Volume 76, Issue 4, pp. 167 - 175. https://doi.org/10.1002/ddr.21258
Abstract
Given nuclear-power-plant incidents such as the 2011 Japanese Fukushima-Daiichi disaster, an urgent need for effective medicines to protect against and treat the harmful biological effects of radiation is evident. To address such a challenge, we describe potential strategies herein including mitochondrial and epigenetic-driven methods using lipoic and butyric acid ester conjugates of carnitine. The antioxidant and other therapeutically beneficial properties of this class of agents may protect against ionizing radiation and resultant mitochondrial dysfunction. Recent studies of the compounds described herein reveal the potential–although further research and development is required to prove the effectiveness of this approach–to provide field-ready radiation-protective drugs.
Description
Please note: this work is permanently embargoed in OpenBU. No public access is forecasted for this item. To request private access, please click on the locked Download file link and fill out the appropriate web form.